PT Nanotech Indonesia Global Tbk (NANO) Fair Value & Analysis
Healthcare · ID · Market cap 90.0B IDR
Fair value as of: Jun 24, 2026
From 23 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 20.85 IDR to 10.55 IDR (−49.4%) since Jun 23, 2026. Share price −15.4% over the past month.
Price vs Fair Value (12 months)
12‑month range 21.95 IDR – 84.68 IDR · fair‑value band 7.91 IDR – 13.18 IDR · the 23.00 IDR price screens above the 10.55 IDR fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
PT Nanotech Indonesia Global Tbk (NANO) currently trades at 23.00 IDR, while our model-based Fair Value estimate is 10.55 IDR — implying the stock looks roughly 54.1% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, PT Nanotech Indonesia Global Tbk generated revenue of 72.2B IDR at a net margin of 2.9%. Revenue declined 70.1% year over year. It earns a return on equity of 0.6%. Net debt stands at 15.7B IDR. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
PT Nanotech Indonesia Global Tbk provides technology and engineering research and development services in Indonesia. The company operates in two segments, Service and Trading. It engages in travel agencies, bureau, tourism, nature tourism information, management consulting, employment, and education businesses, as well as operates in the manufacturing and trading industries. The company was incorporated in 2019 and is headquartered in South Tangerang, Indonesia. PT Nanotech Indonesia Global Tbk is a subsidiary of PT Nanotech Investama Sedaya.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Nanotech Indonesia Global Tbk reported revenue of 72.2B IDR in FY2025 versus 26.8B IDR in FY2021, a compound +28.1%/yr. Reported net income was 2.1B IDR in FY2025, compounding +13.4%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 82.40 MXN | -95% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Nanotech Indonesia Global Tbk (NANO) undervalued?
What is the fair value of NANO?
What is the quality score of NANO?
What is the revenue of PT Nanotech Indonesia Global Tbk (NANO)?
What is the net profit margin of NANO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.